摘要
目的 研究纤支镜肺泡灌洗联合美罗培南治疗重症肺部感染的临床疗效及预后.方法 将2017年6月~2019年6月本院收治的重症肺部感染患者210例依据随机数表法分为对照组和观察组,每组105例.对照组进行常规抗感染治疗,观察组在对照组基础上行纤支镜肺泡灌洗治疗.对比分析两组患者的临床疗效.研究两组患者治疗前后炎症因子水平变化并随访3个月内再住院情况.结果 治疗前,两组CRP、IL-2、IL-4、IL-23相比,差异无统计学意义(P>0.05);治疗后,两组CRP、IL-2、IL-4、IL-23水平均降低,且观察组水平均低于对照组,差异具有统计学意义(P<0.05);与对照组相比,观察组治疗总有效率更高,治疗后3个月内再住院发生率更低,差异具有统计学意义(P<0.05).结论 用纤支镜肺泡灌洗联合美罗培南治疗重症肺部感染可显著提升临床疗效,降低炎症因子水平,改善预后发展,具有临床推荐价值.
Objective To study the clinical efficacy and prognosis of fibrobronchoalveolar lavage combined with meropenem in treatment of severe pulmonary infection.Methods 210 patients with severe pulmonary infection in the hospital from June 2017 to June 2019 were divided into control group and observation group by random number table,with 105 cases in each group.Control group was given routine anti-infection treatment,and observation group was treated with fibrobronchoalveolar lavage based on control group.The clinical efficacy of two groups was compared.The changes of inflammatory factors and re-hospitalization during 3 months of follow-up in two groups were observed.Results Before treatment,there was no statistical difference in the CRP,IL-2,IL-4,IL-23 between two groups(P>0.05);After treatment,the CRP,IL-2,IL-4 and IL-23 in two groups decreased,and the levels of observation group were lower than those of control group(P<0.05);Compared with control group,the total effective rate of observation group was higher,and the incidence of re-hospitalization during 3 months after treatment in observation group was lower(P<0.05).Conclusion Fibrobronchoalveolar lavage combined with meropenem in treatment of severe pulmonary infection can increase clinical efficacy,decrease the levels of inflammatory factors,and improve the prognosis,which is worthy of clinical promotion.
出处
《首都食品与医药》
2020年第13期35-37,共3页
Capital Food Medicine
关键词
重症肺部感染
纤支镜肺泡灌洗
美罗培南
severe pulmonary infection
fibrobronchoalveolar lavage
meropenem
